This study is being conducted to help the investigators better understand how the new FDA approved medication Edaravone (also known as Radicava) works in subsets of patients with ALS. The investigators are also trying to understand if there are specific ALS patients, with different presentations of ALS, who might benefit most from this medication. Also, the investigators are following specific biomarkers to determine the optimal treatment duration in patients with different forms of ALS
There is no study medication being offered in this trial. Edaravone is prescribed as part of regular care. In this trial we are collecting blood, urine, and spinal fluid samples in ALS patients who are taking Edaravone and ALS patients who are not taking Edaravone to measure certain markers that could indicate why the drug may be working in a specific type of ALS.
Either possible, probable, or definite ALS, predominantly lower motor neuron disease, predominantly upper motor neuron disease, or bulbar
With or without cognitive involvement
Willing to participate
On no experimental treatment
Unstable medical illness
Abnormal liver function (>2x ULN)
Unlikely to survive for 26 weeks
Anyone who meets the Inclusion/Exclusion Criteria
Cohort
Prospective
Sample Collection
Other interventionThe investigators will be collecting blood, urine, and spinal fluid samples.
Define pharmacodynamic biomarkers of oxidative stress and antioxidant capacity in different ALS/MND phenotypes.
The investigators aim to identify 4 cohorts of patients with distinct ALS/MND phenotypes and measure a panel of pharmacodynamic biomarkers of oxidative stress and antioxidant capacity in the CSF, blood, and urine.
Click on the lead sponsor to view all of their trials.
Loma Linda University
Lead sponsor
Temple University
Collaborator
Thomas Jefferson University
Collaborator
University of Southern California
Collaborator
Northwestern University
Collaborator
